Lung Cancer
In stage IIIA N2 NSCLC, paclitaxel/carboplatin is an active induction regimen
Published in Cancer Weekly, September 16th, 2003
"The aim of this study was to document the activity and toxicity of paclitaxel (Taxol)/carboplatin when used as induction chemotherapy in patients with stage IIIA N2 non-small cell lung cancer (NSCLC) prior to definitive local treatment within a large, ongoing comparative study (EORTC 08941)," investigators in England report.
"Fifty-two eligible, consenting, chemotherapy-naive patients with NSCLC, median age of 60 years, stage IIIA N2 disease and the ability to tolerate a pneumonectomy, received paclitaxel 200 mg/m2 as a 3-h infusion followed by carboplatin at...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2003-09-16)
More Articles from Cancer Weekly
- Bladder Cancer
Survival rates jump significantly with presurgery chemotherapy - Oncogenes
Research pinpoints gene that increases cancer risk by 26% - Breast Cancer
Elevated DNA damage is significantly associated with breast cancer risk - Cancer Mortality
Progress shown in death rates from four leading cancers - MALT Lymphoma
Gene crucial for antibody-producing cell development is key to blood cell cancer - Transduction
A new adaptor protein reactivates mutant p53 to cause tumor destruction - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
